Canada: RxIP Update - 2016 Year In Review

Last Updated: January 11 2017
Article by Daphne Lainson

The following are highlights of developments in Canadian life sciences intellectual property and regulatory law in 2016, updating our 2016 mid-year highlights.

1. Substantive patent law developments

Utility and the promise doctrine remain unresolved in 2016: The Supreme Court of Canada (SCC) heard AstraZeneca's appeal on November 8 regarding the utility "promise" doctrine and AstraZeneca's patent relating to esomeprazole (NEXIUM). The decision was reserved. Also pending is a decision of the arbitration tribunal regarding the damages claim made by Eli Lilly under the North American Free Trade Agreement (NAFTA). The claim is based on the Canadian judiciary's application of the promise doctrine to patents pertaining to STRATTERA (atomoxetine) and ZYPREXA (olanzapine) as contravening Canada's obligations under NAFTA and the Patent Cooperation Treaty. The hearing concluded on June 8, 2016, and post-hearing submissions were filed on July 25.

Greater clarity is provided on obviousness and double patenting: The Federal Court of Appeal confirmed that the correct test for determining whether an invention is obvious under the "obvious to try" test is still whether it was "more or less self-evident" to try to obtain the invention, and not a lower standard, such as whether the solution provides a "fair expectation of success" or whether "the skilled person had good reason to pursue predictable solutions". The Federal Court of Appeal also clarified the test for double-patenting.

2. Section 8 and other claims following failed PMNOC Regulations proceedings

The Ontario Divisional Court denied Pfizer leave to appeal a decision permitting Apotex's unjust enrichment claim regarding sildenafil to proceed. The Federal Court of Appeal overturned Teva's $125 million award (venlaxafine, EFFEXOR XR) for improper reliance on hearsay evidence and remitted the matter to the trial judge for redetermination. However, the scheduled redetermination by the trial judge has been adjourned while a leave application to the SCC is pending, and if leave is granted, until the appeal is determined. Apotex was denied leave from the SCC regarding a decision striking an unjust enrichment claim against Eli Lilly relating to atomoxetine. However, Apotex's damage claim relating to Apo-Ramipril and based on alleged improper issuance of a patent/a failed prohibition proceeding pursuant to the Trademarks Act and Statutes of Monopolies has been permitted to proceed. The SCC also denied leave in a proposed class action regarding VIAGRA, which sought to allege that consumers had been overcharged as a result of Pfizer's unsuccessful prohibition proceeding.

3. Quantification of damages

The SCC declined to hear Apotex's proposed appeal regarding the relevance of a non-infringing alternative in assessing damages for patent infringement in a case involving lovastatin (MEVACOR). The Federal Court awarded Janssen close to $20 million from Teva for infringing its patent relating to levofloxacin (LEVAQUIN). Teva's appeal is pending.

4. Actions

Bayer prevails in drospirenone/ethinyl estradiol infringement action against Apotex and Cobalt and is entitled to elect between damages and an accounting of profits. On September 9, the Federal Court released a decision finding that Apotex and Cobalt each infringed Bayer's valid patent for an oral contraceptive composition combining drospirenone and ethinyl estradiol. The Court rejected all alleged grounds of invalidity: novelty, obviousness, overbreadth, insufficiency and utility, and granted Bayer a declaration of validity and infringement by Apotex and Cobalt, as well as an order enjoining Apotex and Cobalt from further infringement, and delivery up of any infringing goods. The Court requested written submissions on an election of damages or an accounting of profits. The judgment regarding the injunction and delivery up/destruction as it applied to Apotex has been stayed, and the Court has required that Apotex meet certain conditions including to expedite its appeal. Cobalt has also appealed. On October 27, the Federal Court found that Bayer should be entitled to elect between damages and an accounting of the defendants' profits despite Apotex's argument that it, not Bayer, should decide Bayer's remedy.

5. CETA/TPP

Patent term restoration, on the horizon: On October 31, the day following the signing of the Comprehensive Economic and Trade Agreement (CETA) between Canada and Europe, Bill C-30 was tabled in order to implement CETA. The Second Reading and Referral to Committee was completed on December 13. If passed into law, certificates of supplementary protection (CSPs) will become available, which may provide up to two years patent term restoration for marketing delays resulting from the regulatory approval process. Bill C-30 also provides regulation-making authority to end "dual litigation" under the PMNOC Regulations and the Patent Act. If CETA is not ratified, patent term restoration may still become available in Canada if the Trans-Pacific Partnership (TPP) is ratified. Public submissions on the TPP are being accepted until January 27, 2017, and the fate of the TPP remains uncertain.

6. PMPRB

Planning, reporting and consulting continue: At the end of 2015, the PMPRB released its 2015-2018 Strategic Plan. Reports were released in February analyzing generic drug pricing, in May on public drug plan expenditures, and October saw a Market Intelligence Report: Biologic response modifier agents, 2015, which was highlighted in the PMPRB November NEWSletter. The NEWSletter also reported on the consultations on modernizing pricing guidelines, which began in May to modernize and simplify the framework for determining when patented drug prices are excessive. Phase 1 of the consultation is complete, with the timing of phase 2 of the consultation process to be announced, which will allow stakeholders who provided comments on the PMPRB Discussion Paper an opportunity to make oral submissions. The PMPRB annual report was released, after being tabled in August. The 2015 Annual Report indicates that Canadian patented drug prices remain the third-highest among the seven comparator countries against which the PMPRB reviews prices, behind Germany and the United States. At the end of 2015, 93 investigations into possible excessive patented drug pricing were ongoing.

Judicial challenges to PMPRB jurisdiction unsuccessful, so far: in June, the Federal Court struck Alexion's constitutional challenge of PMPRB provisions in the Patent Act. The Court noted that should leave to appeal be granted in the Sandoz matter, the issue of the constitutionality of the price control regime and the jurisdiction of the PMPRB would be open to consideration by the SCC. However, Sandoz and ratiopharm discontinued their application for leave to appeal on September 8. An appeal by Alexion of its challenge remains pending.

7. Health Canada/CADTH

New transparency initiatives include an expanded Health Canada listing of Regulatory Decision Summaries and Submissions Under Review. Further, flowing from Vanessa's Law, Health Canada released a Draft Guide on Disclosure of Confidential Business Information, an interim approach to drug safety updates, and an Issue Identification Paper for comment regarding mandatory reporting of serious adverse drug reactions by healthcare institutions.

8. Biologics update

Health Canada provides further guidance on biosimilars: New Guidance for biosimilars was adopted on November 14, replacing the Guidance from March 5, 2010. A revised Fact Sheet: Biosimilars was also published.

BIOSIMILAR approvals and litigation continue in 2016: BRENZYS, a product of Samsung Bioepis, was approved on August 31, making it the sixth biosimilar after OMNITROPE (Sandoz, 2009), REMSIMA/INFLECTRA (Celltrion, Hospira, 2014), BASAGLAR (Eli Lilly, 2015), and GRASTOFIL (Apotex, 2015). A PMNOC proceeding concerning Sandoz's etanercept biosimilar is pending; a patent impeachment/infringement trial is on-going for REMSIMA/INFLECTRA and a patent infringement/impeachment action for GRASTOFIL is pending. Amgen's leave to appeal to the SCC the FCA decision dismissing the GRASTOFIL PMNOC proceeding for mootness was denied. For INFLECTRA, the Federal Court upheld a decision summarily dismissing the PMNOC proceeding relating to the IBD indications based on a patent found to "speak specifically and directly to and only to the RA Indications" of infliximab. Janssen is seeking leave to appeal to the SCC the FCA decision finding that a cross-referenced drug submission did not trigger section 5 of the PMNOC Regulations absent early working, resulting in a NOC to Hospira for infliximab.

Other biologics news for 2016 included a settlement of The Children's Hospital of Eastern Ontario (CHEO) action with Transgenomic, allowing "CHEO and all other Canadian public sector hospitals and laboratories the right to test Canadians for Long QT syndrome on a not-for-profit basis ... without legal roadblocks from [the] gene patents." In addition, CIPO has signalled a change in practice for humanized antibodies with a decision clarifying support requirements.

9. Patent litigation practice

A "quia timet" patent infringement claim was allowed to proceed, with the Federal Court dismissing Teva's motion to strike a patent infringement claim by Gilead made further to Teva's impeachment action regarding patents relating to tenofovir disoproxil fumarate products (TRUVADA and VIREAD). Valeant's prohibition application under the PMNOC Regulations in respect of metformin (Valeant's GLUMETZA) was struck as an abuse of process upon a section 6(5)(b) motion brought by Apotex. New case management guidelines for PMNOC applications were released in May. The "blinding" of experts in PMNOC applications (e.g. as to the generic's product) continues to have mixed results: one judge found it not determinative; another weighed it as a relevant factor in preferring one expert's testimony over another, while another found the 'blinding' of experts was not a reason to prefer one expert's opinion over another's opinion. In another decision, the Court found that the blinding issue is a question of relevance, reliability and weight rather than a doctrinal matter, and therefore approached the evidence on a case-by-case basis.

10. Competition law

In March, the Competition Bureau released updated Intellectual Property Enforcement Guidelines which describe the Bureau's approach to conducting investigations of potentially anti-competitive activities relating to intellectual property, including settlements in PMNOC proceedings and "product switching". In October 2016, the Competition Bureau released a report questioning restrictions on health care advertising.

11. PMNOC Regulations and data protection statistics

Based on the 8 Federal Court PMNOC Regulations decisions reported by year-end, the patentee was successful on the merits on 3 patents in 3 cases and the generic manufacturer was successful on 6 patents in 6 cases. The FCA affirmed all 5 PMNOC Regulations appeals (patentee on 3 patents; generic manufacturer on 2 patents). See summary table here. See also the Therapeutic Products Directorate report providing a statistical overview of Health Canada's administration of the PMNOC Regulations and data protection; and the Therapeutic Products Directorate and the Biologics and Genetic Therapies Directorate's Drug Submission Performance Annual Reports.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Daphne Lainson
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.